Bluejay Diagnostics (BJDX) Income towards Parent Company (2020 - 2026)
Bluejay Diagnostics (BJDX) reported Income towards Parent Company of -$2.0 million for Q1 2026, down 5.79% on a YoY basis from -$2.1 million in Q1 2025, and down 41.22% sequentially from -$1.4 million in Q4 2025.
Bluejay Diagnostics (BJDX) Income towards Parent Company (2020 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 7 years of Income towards Parent Company data on file, last reported at -$2.0 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 5.79% year-over-year to -$2.0 million; the trailing twelve-month figure through Mar 2026 stood at -$7.0 million (up 12.52% YoY), and the FY2025 full-year result was -$18.9 million, down 11.06% from the prior year.
- Income towards Parent Company fell to -$2.0 million in Q1 2026, from -$1.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$1.4 million in Q4 2025 to a low of -$3.0 million in Q2 2023.
- A 5-year average of -$2.2 million and a median of -$2.1 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company plunged 791.77% in 2022 and surged 36.48% in 2024, its largest moves.
- Tracing BJDX's Income towards Parent Company over 5 years: stood at -$2.5 million in 2022, then rose by 2.39% to -$2.4 million in 2023, then climbed by 12.77% to -$2.1 million in 2024, then soared by 32.53% to -$1.4 million in 2025, then sank by 41.22% to -$2.0 million in 2026.
- Business Quant data shows BJDX's Income towards Parent Company at -$2.0 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Bluejay Diagnostics | 1.07 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.02 Mn |
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.97 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.44 Mn |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -2.35 Mn |
| Jun 30, 2023 | -3.00 Mn |
| Mar 31, 2023 | -2.72 Mn |
| Dec 31, 2022 | -2.49 Mn |
| Sep 30, 2022 | -2.91 Mn |
| Jun 30, 2022 | -2.13 Mn |
| Mar 31, 2022 | -2.10 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Sep 30, 2021 | -1.69 Mn |
| Jun 30, 2021 | -689,390.00 |